PRAME Monoklonaler Antikörper

• Featured Product
• KD/KO Validated

PRAME Monoklonal Antikörper für IF

Wirt / Isotyp

Maus / IgG2b

Getestete Reaktivität

human, Maus, Ratte

Anwendung

IF

Konjugation

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1E9G9

Kat-Nr. : CL488-68097

Synonyme

MAPE, OIP 4, OIP4, Opa interacting protein 4, PRAME

---

Galerie der Validierungsdaten

• 

  IF Staining of HaCaT using CL488-68097

  Immunofluorescent analysis of (4% PFA) fixed HaCaT cells using CoraLite® Plus 488 PRAME antibody (CL488-68097, Clone: 1E9G9 ) at dilution of 1:100, CL594-phalloidin (red).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF: HaCaT-Zellen

Empfohlene Verdünnung

• Immunfluoreszenz (IF): IF : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-68097 bindet in IF PRAME und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Maus / IgG2b
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: PRAME fusion protein Ag1906
• Vollständiger Name: preferentially expressed antigen in melanoma
• Berechnetes Molekulargewicht: 509 aa, 58 kDa
• Beobachtetes Molekulargewicht: 50 kDa
• GenBank-Zugangsnummer: BC014074
• Gene symbol: PRAME
• Gene ID (NCBI): 23532
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: BS mit 50% Glyzerin, 0,05% Proclin300, 0,5% BSA, pH 7,3.
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.